T he long-term use of benzodiazepines is concerning because of the risk of dependence, cognitive impairment, and falls and fractures. [1] [2] [3] [4] Patients aged 65 years and older are particularly susceptible to the side effects of benzodiazepines. 5, 6 For instance, the use of benzodiazepines increases the risk of hip fracture in older individuals by at least 50%. 5 Given the high morbidity and mortality of many of these side effects, the benefits of benzodiazepines for older individuals are unclear, especially as one-third of long-term users do not display psychiatric symptoms requiring benzodiazepines. 7 There have been explicit guidelines on the inappropriateness of benzodiazepine prescription in older patients dating back to 1991. One example is Beers' criteria or list. [8] [9] [10] This was originally developed for nursing home patients, 8 but later modified to apply to all patients aged 65 years and older. 9, 10 It identified 20 medications that should be completely avoided, such as diazepam and chlordiazepoxide, and others where a specified dosage and duration should not be exceeded (for example, prescription of more than one month of a short-acting benzodiazepine). 8, 9 In spite of this, epidemiologic data from Europe, Canada, Japan, and Australia indicate that rates of benzodiazepine use in the general population have remained steady at around 6%. [11] [12] [13] [14] [15] Further, in spite of their greater susceptibility to adverse effects, rates of long-term benzodiazepine use among those aged 65 years and older are actually reported to be higher than those of the general population (11% to 25%). [16] [17] [18] International comparisons can provide information on the influence of differing access to health care services and drug insurance programs, formulary policies, and practitioner and public education initiatives on drug use trends and consequences. [19] [20] [21] [22] For example, access to benzodiazepines and related drugs in Australia and the province of Nova Scotia differs significantly regarding both drug availability and reimbursement policies by public insurers, with only 4 agents having equivalent status (Table 1) . Nova Scotia has more benzodiazepines and related drugs on the market than Australia and more agents eligible for open coverage by public insurance (14 and 5, respectively), but it is not known whether this difference has any effect on prescribing and use. The hypothesis to be tested was that use of benzodiazepines and related compounds, in those aged 65 years and older and those receiving social security payments, is similar in Nova Scotia and Australia.
Methods

Data Sources
In The study had approval from the Dalhousie University ethics committee (2005-1052) in Halifax, Nova Scotia. As aggregated de-identified data were used for Australia, ethics committee approval was not required.
Comparing the Quantity of Use
We recorded the use of each individual benzodiazepine and related compounds, and total overall use each month, during a 4-year period from 2000 to 2003. Prescriptions were converted to DDDs. 26, 27 This standard measure represents the average maintenance dose for each day of a drug when used for its major indication. It overcomes difficulties in comparing prescriptions of different price, pack size, duration, and dose by relating all drug use to a standardized unit. We calculated the number of DDDs for each 1000 concession beneficiaries each day (DDD/1000 beneficiaries/day) to compare usage over time and place. 28 Mean annual data points were compared within and between each study site. 
Comparing the Quality of Use
DU90% measures the number of medications that form 90% of prescribing for a particular drug class. Lower scores have been proposed to provide an indicator of the quality of drug prescribing. 21 This is because a small range of medications for any drug class allows physicians to gain a greater knowledge of the available treatments. 21 Prescribers, therefore, know more about benefits, risks, and dosage regimes, and may be less susceptible to industry promotion, if they only have to become familiar with a smaller number of compounds. 29 In this study, we calculated the number and volume of drugs that accounted for 90% of the total DDD/1000 beneficiaries/day for benzodiazepines and related compounds. The drugs were ranked from highest use to lowest use, as a percentage of the total DDD/1000 beneficiaries/day. The drugs that constitute 90% of total use are referred to as DU90%.
Data Analysis
We performed linear regressions and Student t tests to compare changes in the prescription of benzodiazepines and related compounds over time and jurisdiction (GraphPad Prism version 4.03, GraphPad Software, San Diego, California). Differences in the rate of increase were considered statistically significant at P < 0.05.
Results
The number of Pharmacare beneficiaries in Nova Scotia ranged from a high of 169 000 in 2000 to a low of 155 000 in 2003 as Pharmacare became the insurer of last resort and dropped coverage for those with other insurance. The number of concession beneficiaries in Australia ranged from 4 800 000 in 2000 to 5 000 000 in 2003. The 2 populations were similar in terms of age and gender; 62% and 68% were aged 65 years or older in Nova Scotia and Australia, respectively, and the proportion of women were 58% and 56%. The prevalence of self-reported mental illness was 11.1% (95%CI, 9.5 to 12.8) in Nova Scotia, 30 and 10.5% in Australia. 15 The use of benzodiazepines increased at a steady but comparable rate in both areas. However, the use of benzodiazepines in Nova Scotia was more than double that of Australia from 2000 to 2003 (Figure 1 ). The observed increases over this period were 15.5 (12.5%) and 9.2 (19%) DDD/1000 beneficiaries/day in Nova Scotia and Australia, respectively. The rate of increase did not differ between the jurisdictions (P = 0.12).
There was greater variety in benzodiazepine prescribing in Nova Scotia as indicated by DU90% (Figure 2 
Discussion
This is the first study to directly compare 2 jurisdictions using a standard methodology, and is particularly relevant at a time when Canada consolidates its National Pharmaceutical Strategy. 31, 32 We have shown that the use of benzodiazepines increased at a steady but comparable rate in both Australia and Nova Scotia. Of most concern to Canadian prescribers was the finding that the use of benzodiazepines in Nova Scotia was more than double that of Australia from 2000 to 2003, even though the health systems in both countries have similar characteristics. 25, 33 This may be relevant to physicians elsewhere in Canada because the Atlantic region has, if anything, significantly lower benzodiazepine use than the rest of the nation. 19 All this exists despite numerous initiatives to improve rational prescription including the use of clinical practice guidelines, electronic decision support tools, formularies, copayments, therapeutic and generic substitution policies, and education of doctors and pharmacists. 24, [34] [35] [36] [37] Of particular concern is the continuing use of long-acting benzodiazepines that are contraindicated in the elderly. 8, 9 Our results from Australia and Canada confirm findings from the United States that benzodiazepines with longer half-lives such as diazepam and nitrazepam are some of the most common compounds prescribed.
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Implications for Clinical Practice and Policy Change
Improving health status and reducing health care costs are major themes of health care policies worldwide. To achieve these goals, medicines need to be prescribed and used appropriately. For this reason, policies and guidelines for prescribing have been designed. 32, 39 Guidelines for benzodiazepines and related compounds, including the Beers' list, [8] [9] [10] recommend that benzodiazepine use should be limited in the elderly to low dosages of a short-or medium-acting agent for no more than one month. [8] [9] [10] 40 However, the results of our study suggest these are not being implemented. Indeed, benzodiazepine use is increasing in this vulnerable population, and use in Nova Scotia is more than twice the use in Australia. Prescriber-related factors contributing to this increase in use could include knowledge, confusion over differing psychotropic guidelines, difficulties in discontinuing an inappropriate medication started by a previous physician, multiple prescribers and pharmacies involved in the care of a patient, negative perceptions regarding aging, and cost issues. 41 Patients may contribute to the problem by demanding an inappropriate medication. Finally, the inclusion or exclusion of specific medications in hospitals, health care plans, or provincial formularies may exacerbate the problem through the inclusion of excessive number of compounds for a given medication class. 38 Successful strategies to foster appropriate prescribing need to address all of these factors through educational and administrative approaches. 38 For physicians, these strategies include educational approaches such as one-on-one sessions and academic detailing. Education could be complemented by the use of personal formularies, where prescribers have a short personal list of drugs that are effective for, and tolerated by, the patients they treat. 29, 38 This technique can be easily taught to medical students through textbooks, national formularies, and guidelines. 42 Evidence also suggests that most seniors can be gradually tapered off benzodiazepines, while avoiding negative effects of withdrawal. 43 Media campaigns and letters to patients can encourage them to gradually discontinue their benzodiazepine in partnership with their family physician. 44 Initiatives such as these can achieve 20% to 30% reductions in long-term benzodiazepine use. [45] [46] [47] [48] Our data also suggest an association between the number and range of benzodiazepines prescribed. Nova Scotia reimburses 17 benzodiazepines, while Australia only reimburses 5.
Administrative approaches could therefore include limits on the range of medications available for any particular drug class, allowing physicians to gain greater knowledge of the medications they prescribe.
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Limitations of This Study
This study used administrative databases designed for pharmacist payment rather than for drug usage studies, which lack clinical data related to patient characteristics and reason for use. Therefore these data need to be interpreted with care. The databases do not allow individual tracking of patients, therefore coprescribing with other medication, or doubling or tripling the dose on benzodiazepine use cannot be quantitated. The data indicated dispensed medication (rather than actual prescribed medicine or actual taken medicine), and so do not take into account primary noncompliance (medication prescribed but the prescription not filled) or noncompliance by the patient (medication prescribed and dispensed but not actually taken by the patient). The data are only available for subsidized medicines, dispensed to individuals aged 65 years and older, not otherwise insured, or receiving social benefits (and therefore entitled to subsidized medicines) in Nova Scotia, or dispensed to those receiving an old-age pension, or receiving social security benefits in Australia. The groups are essentially similar, in particular the proportion aged 65 years and older, but there may be some minor differences in the populations. We were only able to compare the Australian data with data from one Canadian province; we therefore do not know how generalizable the findings would be to other parts of Canada. The DDD methodology may not reflect the actual dosage taken, especially if the medication was not used regularly. The knowledge, skills, and attitudes about benzodiazepine prescribing among physicians and the beliefs and values among patients may also be different in Nova Scotia and Australia.
Conclusion
This study found major differences in the type and rate of benzodiazepine prescribing in Nova Scotia and Australia. Benzodiazepine use increased in both Nova Scotia and Australia during the period, with benzodiazepine usage being twice as high in Nova Scotia than Australia. Of particular concern was the continuing use of long-acting benzodiazepines, which are contraindicated in this age group. 8, 9 This study has suggested that the high use of benzodiazepines in Nova Scotia may be due to Nova Scotia having 12 more benzodiazepines (and related compounds) available than Australia. It may be possible to achieve a decrease in use by promoting the use of guidelines and enhancing awareness of the level and burden of benzodiazepine use, especially in those aged 65 years and older. The effects of different formulary policies of drug insurance programs, funding, beliefs and attitudes of patients and prescribers, and education therefore merit further investigation. 
Conclusions :
De grandes différences existent entre le type et le taux des prescriptions de benzodiazépines en Nouvelle-Écosse et en Australie, la Nouvelle-Écosse déclarant plus que le double de l'utilisation. L'utilisation de benzodiazépines augmente dans les deux territoires. Les résultats canadiens sont particulièrement préoccupants car il a été signalé que l'utilisation de benzodiazépines était moindre dans les provinces atlantiques que dans les autres provinces. Les variations entre les 2 territoires peuvent être attribuables à des facteurs comme l'offre réduite de benzodiazépines en Australie, les différences chez les prescripteurs, les attitudes et le comportement des patients, ou les différentes initiatives influençant l'utilisation de benzodiazépines.
